How pharma can productively coexist with PBMs—and still lower drug costs faster.
Mark Thierer, EVERSANA
Advertisement
CEO of EVERSANA
Articles by Mark Thierer, EVERSANA
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
The Great Repricing: How Pharma Must Evolve for Three Diverging Payer Economies
2
Trade & Channel Strategies 2025: Inside Pharma’s Turning Point
3
Pharma Pulse: Amgen's Uplizna Secures CD19 Approval for Myasthenia Gravis, as Asthma Biologic Switches Highlight Efficacy Expectations Gap
4
A 'Beautiful Fake': Pharma Fraudsters Upping Their Game
5
